Revenue
Margin
Demand
Guidance
Tone
Metrics raised 2
- PL membership fee hiked from ₹99 to ₹149, expected to add ₹10–11 crores to FY27 top line
- Private label mix target set to grow 0.25–0.5% per quarter, recovering from the current decline
Metrics cut 4
- Full-year revenue growth guidance deferred to Q2 (no explicit FY27 revenue growth guidance provided)
- Full-year margin guidance deferred to Q2 (margin recovery targeted, but full-year guide after Q2)
- Non-core capex put on hold: food park/oil extraction unit (₹40 crores) and wellness services facility paused
- Diagnostics expansion paused: significant radiology expansion on hold; B2C membership below 2.5–3 lakh target, now in maintenance mode
Event Participants
Executives
3
D R N Srinivas, Madhukar Gangadi, Sujit Kumar Mahato
Analysts
12
Akash Shah, Akhil Parekh, Anil Sarin, Ankit Bansal, Axay Shah, Bino Pathi, Divyansh Gupta, Jasdeep Walia, Jitaksh Gupta, Saion Mukherjee, Sudarshan Agarwal, Swaraj Mehta
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹1,879.6 crores | Pharmacy revenue grew 21.8% YoY; Q1 achieved 99.9% of annual operating plan revenue. |
| Store Network | 5,476 stores | Net adds +146 in Q1 (222 gross openings, 52 closures incl. 27 franchisee); vs 4,813 at Jun 2025; FY27 target of 800 net adds maintained. |
| Store Area | 2.9 mn+ sq ft; avg 539 sq ft | vs 2.5 mn+ sq ft at Jun 2025; 47–48 large-format stores lifting average size. |
| Private Label Share | 20% of revenue (pharma 10.7%, non-pharma 9.3%) | Pharma PL mix down ~200 bps YoY; absolute pharma PL flat at ~₹197–200 crores; non-pharma PL hit by diaper supply disruptions. |
| Diagnostics Revenue | ₹37.1 crores | +22.4% YoY (₹30.3 crores in Q1 FY26); operating EBITDA ₹6.6 crores vs ₹4.1 crores (~+60% YoY). |
| Consolidated Operating EBITDA | ₹65.1 crores; 3.5% margin | Down QoQ/YoY on PL mix, inventory provision normalisation and labour cost hikes; annual plan maintained. |
| Pharmacy Operating EBITDA | ₹58.8 crores; 3.2% margin | Store-level EBITDA margin 10.4% for >12-month stores; 4.3% after non-store costs. |
| Working Capital | 54 days | Warehouse inventory 33 days; first-year stores at 100 days vs 36 days for >12-month stores. |
| Inventory Provision | ~₹11–12 crores in Q1 | vs ₹4.5–5 crores in Q4 FY26 (exceptionally low due to provision release); normal run-rate ~0.8–1% of annual sales. |
| PL Plan Members | ~44–45 lakh active | vs ~39–40 lakh in Jun 2025; membership fee raised from ₹99 to ₹149 in Jun 2026; ~₹10–11 crores FY27 top-line benefit. |
| Cash / Debt | Cash ₹600+ crores; debt-free | Promoter debt separate at ~₹1,150 crores incl. interest; no reduction timeline. |
Geographic & Segment Commentary
- Pharmacy Retail: Network expanded to 5,476 stores (+146 net in Q1; 222 gross openings, 52 closures, 24 COCO→franchise conversions in progress). Pharmacy revenue grew 21.8% YoY; stores >12 months contributed 94% of pharmacy revenue at 10.4% store-level EBITDA margin. Private label share was 20% of revenue, with pharma PL mix down ~200 bps YoY on a deliberate rebalancing towards branded customers.
- Diagnostics: Revenue grew 22.4% YoY to ₹37.1 crores with operating EBITDA of ₹6.6 crores; plan sales per day rose from 552 in April to 644 in June with ~2 lakh active clients. However, membership is below the 2.5–3 lakh target and management has paused significant radiology expansion.
- Franchisee Model: Q1 net franchisee adds were 131 of 146 total net stores; 27 franchisee outlets closed (average age 0.7 years) due to expectation mismatch among first-time entrepreneurs. Model adjustments include faster break-even support and first-year fee assistance; 24 COCO stores are converting to franchisee, predominantly taken by senior employees.
- Geographic Expansion: Expansion continues in contiguous states (Maharashtra, Chhattisgarh, Madhya Pradesh, Kerala); management will move further north/west only after these clusters turn profitable. Core-business capex on stores and warehouses continues.
Company-Specific & Strategic Commentary
- Capex on Hold: Board-approved food park/oil extraction unit (₹40 crores) and wellness services facility have been put on hold after market and investor feedback; management will evaluate fund utilisation. Core business capex is unaffected.
- Private Label Recovery: Strategy is to arrest PL mix decline and grow share 0.25–0.5% per quarter through outside-store influencer advertising and improved employee selling; non-pharma supply disruptions (diapers) expected to normalise by end of Q2 FY27.
- Cost Optimisation: Minimum wage hikes (Karnataka +60%, Telangana +25%) effective June 1, 2026 will hit full quarter from Q2; retention bonus plan stopped for new hires from March 1, 2026; non-statutory incentives being restructured.
- Pricing Actions: Effective July 7, 2026, discounts on purchases >₹1,000 were cut from 20% to 19% for non-UPI payments; PL membership fee raised from ₹99 to ₹149, expected to add ₹10–11 crores to FY27 top line.
- Capital Returns: With cash of ₹600+ crores and a debt-free balance sheet, management is evaluating dividend/buyback options and will update after Board discussion.
- Competitive Positioning: Management is not reacting to quick commerce; views the model as cash-burning and does not see a sustainable 20% discount + free delivery + 10-minute service for pharmacy.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Store Additions | 800 net new stores in FY27 (incl. franchisee) | Reiterated; Q1 net adds of 146; mix likely franchisee-heavy after 131 net franchisee adds in Q1. |
| Revenue | FY27 AOP revenue on track | Q1 achieved 99.9% of annual operating plan; explicit full-year revenue growth guidance deferred to Q2. |
| Operating EBITDA | ~₹400+ crores consolidated for FY27 (AOP) | Maintained despite Q1 gap; management confident of covering shortfall via PL recovery, discount tweaks and cost measures. |
| Private Label Mix | +0.25–0.5% share per quarter | Recovery to start after supply disruptions resolve; pharma and non-pharma both targeted. |
| Gross Margin | Recover 100 bps PL and 40 bps supplier-discount drag in FY27 | 70 bps inventory provision impact normalises at ~₹11–12 crores/quarter; full-year margin guidance after Q2. |
| Diagnostics | Maintenance mode; no significant expansion | B2B growth weak; B2C members ~2.2 lakh vs 2.5–3 lakh target. |
| Capital Allocation | Non-core capex on hold; dividend/buyback evaluation | Board update expected next quarter; core business capex continues. |
Risks & Constraints
| Risk | Context |
|---|---|
| Labor cost inflation | Karnataka and Telangana minimum wage hikes (60% and 25%+) effective June 1, 2026; Q1 carried only one month impact, full effect from Q2. Mitigations: retention plan stopped, incentive restructuring, PL mix recovery. |
| Private label margin drag | PL mix declined ~200 bps YoY (pharma) and non-pharma supply disruptions (diapers) hurt Q1; if 0.25–0.5% quarterly recovery fails, gross margin and AOP EBITDA could be missed. |
| Franchisee churn | 27 franchisee closures in Q1 with average store age of 0.7 years; expectation mismatch persists; model still experimental and may weigh on expansion pace. |
| Competitive discounting | Quick commerce scaling in cities with subsidised delivery and discounts; management not engaging, but sustained aggression could pressure pharmacy footfall and pricing. |
| Inventory obsolescence | Private label is made-to-order, carrying up to 5% of PL sales as normal provision; current total provision ~0.8–1% of sales. Any demand or supply shock increases charges. |
| Promoter leverage overhang | Promoter debt of ~₹1,150 crores incl. interest remains; no timeline for reduction, which may continue to be a sentiment overhang for the stock. |
Q&A Highlights
Capex Plan Put on Hold
- Question: Why put approved capex (₹40 cr food park/oil extraction, wellness facility) on hold and what's the strategic direction? (Sudarshan Agarwal - Axis Capital)
- Answer: Further deliberation; non-core capex paused; backward integration was to secure new-product supply chains, but no longer being pursued at MedPlus; fund utilisation to be communicated later. (Madhukar Gangadi)
- Question: What changed within hours of Board approval? (Saion Mukherjee - Nomura)
- Answer: Strong market reaction and investor feedback; company is sensitive to market sentiment; core business capex (stores, warehousing) continues irrespective. (Madhukar Gangadi)
Private Label Decline and Recovery
- Question: What caused the PL share contraction and what is the trajectory? (Sudarshan Agarwal - Axis Capital)
- Answer: Early adoption peaked; employee push was excessive; focus now on full customer service, which grew branded sales faster; PL absolute continues to grow; target to arrest decline and build at 0.3–0.5% per quarter through influencer ads and better selling skills. (Madhukar Gangadi)
- Question: How many active plan members and what's the pricing change? (Saion Mukherjee - Nomura)
- Answer: ~44–45 lakh active members vs ~39–40 lakh a year ago; membership fee raised from ₹99 to ₹149 a month ago; expected ₹10–11 crores incremental FY27 top line, flowing through to bottom line. (Sujit Mahato)
- Question: What is the GM sensitivity to every 30 bps PL share increase? (Akash Shah - Investec)
- Answer: Previous quarter's guidance stands; sensitivity varies between pharma and non-pharma categories. (Sujit Mahato)
Margin Bridge: QoQ Gross Margin Decline
- Question: Why did gross margin fall ~200 bps QoQ? (Anil Sarin - K16 Advisors)
- Answer: 100 bps from PL mix (pharma + non-pharma), 70 bps from inventory provision normalisation (Q4 had a release; Q1 charge ₹11–12 cr vs ₹4.5–5 cr), 40 bps from absence of year-end supplier discounts. Expected to recover 100 bps + 40 bps over FY27; provision normalises at ~₹12 cr/quarter. (Sujit Mahato)
- Question: Why did EBITDA fall YoY when no segment de-grew in absolute terms? (Bino Pathi - Elara Capital)
- Answer: Mix impacted gross profit; employee cost increase is the main expense driver; pharma PL absolute was flat YoY at ~₹197 cr vs ₹200 cr. (Sujit Mahato)
Labor Cost Inflation and Retention
- Question: What's behind elevated employee costs? (Saion Mukherjee - Nomura)
- Answer: Full-quarter impact of warehouse hires; Karnataka minimum wages +60%, Telangana +25%+, effective June 1, 2026 (only one month in Q1); retention bonus stopped for new hires; optimising non-statutory incentives; PL recovery will help offset. (Sujit Mahato)
- Question: Will stopping the retention plan hurt attrition? (Divyansh Gupta - Latent PMS)
- Answer: Higher wages should attract better talent; accrued retention amounts for existing employees will be paid; company will monitor and intervene if needed. (Sujit Mahato)
Franchisee Model: Closures and Adjustments
- Question: Why did closed franchise stores have average age of just 0.7 years? (Divyansh Gupta - Latent PMS)
- Answer: Expectation mismatch among first-time entrepreneurs; in ~99% of cases company helps exit or finds replacement; model tweaks include faster break-even support and first-year fee assistance. (Sujit Mahato)
- Question: Is the 800-store guidance a net number and what's the mix? (Akhil Parekh - 360 ONE Capital)
- Answer: Net; 800 maintained; Q1 net adds 146, of which 131 franchisee; 24 COCO→franchise conversions >95% taken by senior employees. (Sujit Mahato)
Diagnostics: Subdued Expansion Plans
- Question: How do you plan to scale diagnostics? (Jasdeep Walia - Clockvine Capital)
- Answer: Diagnostics is profitable, but below plan; B2B subscription hasn't scaled; B2C members ~2.2 lakh vs 2.5–3 lakh target; only maintenance spend on radiology, no major expansion. (Madhukar Gangadi)
Inventory Provisioning on Private Label
- Question: Is the inventory charge mainly PL? (Jasdeep Walia - Clockvine Capital)
- Answer: ~0.8–1% of total sales annually; predominantly PL; up to 5% of PL sales is a normal range; branded products are mostly returnable. (Madhukar Gangadi)
- Follow-up: Will this expense come down? (Jasdeep Walia)
- Answer: Management will work to minimise; any reduction is direct bottom-line benefit. (Madhukar Gangadi)
Capital Allocation & Promoter Leverage
- Question: With ₹600+ cr cash, any dividend or buyback plans? (Akhil Parekh - 360 ONE Capital)
- Answer: Evaluating options; will present to Board and update next quarter. (Sujit Mahato)
- Question: What is current promoter debt outstanding? (Anil Sarin - K16 Advisors)
- Answer: ~₹1,150 crores including interest; reduction is a family office decision with no current timeline; disclosures will follow if any action. (Sujit Mahato)
Quick Commerce Competition
- Question: Quick commerce is scaling in cities; impact on MedPlus? (Axay Shah - VVD Asset Managers)
- Answer: Not a focus; players are cash-burning and subsidising delivery; pharmacy has inherent challenges for 10-minute model; no meaningful impact expected. (Madhukar Gangadi)
FY27 Guidance and Margin Outlook
- Question: Should margins recover to FY26 levels in FY27? (Akhil Parekh - 360 ONE)
- Answer: Too early to commit; allow one quarter to assess discount tweak, PL recovery and membership fee benefits; updated full-year outlook after Q2. (Sujit Mahato)
- Question: Is SSSG tracking 9–10%? (Akash Shah - Investec)
- Answer: Company does not formally track SSSG due to self-cannibalisation from store densification; internal focus is on an overall ~10% growth benchmark. (Sujit Mahato)
Key Takeaway
MedPlus kicked off FY27 with 21.8% YoY pharmacy revenue growth and consolidated revenue of ₹1,879.6 crores, but consolidated operating EBITDA margin dipped to 3.5% (₹65.1 crores) on private-label mix pressure, inventory provision normalisation and minimum wage hikes in Karnataka (+60%) and Telangana (+25%). Management re-affirmed 800 net store additions for FY27 (146 added in Q1, franchisee-heavy) and the ~₹400+ crore annual operating EBITDA plan, while shelving non-core capex (food park, wellness) after investor feedback. Recovery actions include a PL membership fee hike (₹99→₹149), a 1% discount cut for non-UPI purchases above ₹1,000, and a 0.25–0.5% quarterly PL mix target. Diagnostics grew 22% YoY but expansion is paused. Watch items: full-quarter labour cost impact, franchisee churn, and ~₹1,150 crore promoter debt.